Furthermore, melatonin inhibits matrix metalloproteinase (MMP) activation and significantly inhibits the NF-κB signaling pathway, which is essential for the treatment of AAA (Tai et al., 2010; Chang et al., 2012; Shi et al., 2012; Rudra et al., 2013). The gene discussed is NFKB1; the disease is triple-A syndrome.